Successful use of intravenous treprostinil as a bridge to pulmonary thromboendarterectomy.
Ashley CattranJean M ElwingPublished in: BMJ case reports (2021)
Chronic thromboembolic pulmonary hypertension (CTEPH) involves non-resolving thromboemboli in the pulmonary arteries. Treatment for CTEPH includes lifelong anticoagulation and determination of patients who have disease which is operable versus inoperable. Pulmonary arterial hypertension (PAH) targeted therapies are oftentimes used as a bridge to pulmonary thromboendarterectomy (PTE), though riociguat is the only Food and Drug Administration (FDA)-approved therapy for CTEPH. There is a paucity of data regarding the efficacy of other PAH therapies, particularly as a bridge to PTE. Here, we present a case report of severe CTEPH related to ventriculoatrial shunt in which intravenous treprostinil was used as a bridge to PTE.
Keyphrases
- pulmonary hypertension
- pulmonary arterial hypertension
- pulmonary artery
- drug administration
- end stage renal disease
- high dose
- atrial fibrillation
- newly diagnosed
- chronic kidney disease
- prognostic factors
- electronic health record
- early onset
- venous thromboembolism
- machine learning
- low dose
- locally advanced
- rectal cancer
- artificial intelligence
- human health